Royalty Pharma plc (NASDAQ:RPRX) Receives Average Recommendation of “Buy” from Brokerages

Royalty Pharma plc (NASDAQ:RPRX) has been given a consensus rating of “Buy” by the four analysts that are currently covering the company, MarketBeat reports. Four equities research analysts have rated the stock with a buy rating. The average 1-year price target among brokers that have issued ratings on the stock in the last year is $53.25.

A number of analysts recently issued reports on the company. TheStreet raised Royalty Pharma from a “d+” rating to a “c” rating in a research report on Thursday, June 15th. StockNews.com assumed coverage on Royalty Pharma in a report on Thursday, August 17th. They set a “hold” rating for the company. Finally, Morgan Stanley lifted their price target on Royalty Pharma from $52.00 to $53.00 and gave the stock an “overweight” rating in a report on Wednesday, August 9th.

Insider Transactions at Royalty Pharma

In other news, EVP George W. Lloyd sold 19,215 shares of Royalty Pharma stock in a transaction that occurred on Monday, June 5th. The shares were sold at an average price of $33.54, for a total value of $644,471.10. Following the completion of the sale, the executive vice president now directly owns 109,099 shares in the company, valued at $3,659,180.46. The transaction was disclosed in a document filed with the SEC, which can be accessed through this link. In other news, CFO Terrance P. Coyne sold 37,500 shares of the company’s stock in a transaction on Wednesday, July 12th. The shares were sold at an average price of $31.07, for a total transaction of $1,165,125.00. Following the completion of the transaction, the chief financial officer now directly owns 902,500 shares in the company, valued at $28,040,675. The sale was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this link. Also, EVP George W. Lloyd sold 19,215 shares of the company’s stock in a transaction on Monday, June 5th. The stock was sold at an average price of $33.54, for a total transaction of $644,471.10. Following the transaction, the executive vice president now owns 109,099 shares of the company’s stock, valued at $3,659,180.46. The disclosure for this sale can be found here. Insiders sold a total of 188,122 shares of company stock worth $6,120,628 over the last quarter. Company insiders own 18.72% of the company’s stock.

Institutional Trading of Royalty Pharma

Several institutional investors have recently modified their holdings of RPRX. Dark Forest Capital Management LP bought a new stake in shares of Royalty Pharma in the fourth quarter worth $30,000. Sageworth Trust Co bought a new position in shares of Royalty Pharma during the 1st quarter worth about $31,000. Parallel Advisors LLC boosted its position in shares of Royalty Pharma by 454.6% during the 1st quarter. Parallel Advisors LLC now owns 904 shares of the biopharmaceutical company’s stock worth $33,000 after purchasing an additional 741 shares in the last quarter. Captrust Financial Advisors boosted its position in shares of Royalty Pharma by 210.8% during the 2nd quarter. Captrust Financial Advisors now owns 805 shares of the biopharmaceutical company’s stock worth $34,000 after purchasing an additional 546 shares in the last quarter. Finally, International Assets Investment Management LLC acquired a new stake in shares of Royalty Pharma in the 1st quarter worth about $42,000. Institutional investors own 48.06% of the company’s stock.

Royalty Pharma Price Performance

NASDAQ:RPRX opened at $30.21 on Friday. The company has a debt-to-equity ratio of 0.62, a quick ratio of 2.52 and a current ratio of 2.52. The stock’s 50-day simple moving average is $30.55 and its 200 day simple moving average is $33.48. The company has a market cap of $18.18 billion, a P/E ratio of 70.26, a P/E/G ratio of 1.50 and a beta of 0.38. Royalty Pharma has a 52-week low of $28.98 and a 52-week high of $44.47.

Royalty Pharma Announces Dividend

The company also recently disclosed a quarterly dividend, which will be paid on Friday, September 15th. Stockholders of record on Friday, August 18th will be issued a dividend of $0.20 per share. This represents a $0.80 dividend on an annualized basis and a dividend yield of 2.65%. The ex-dividend date of this dividend is Thursday, August 17th. Royalty Pharma’s dividend payout ratio is presently 186.05%.

About Royalty Pharma

Royalty Pharma plc operates as a buyer of biopharmaceutical royalties and a funder of innovations in the biopharmaceutical industry in the United States. It is also involved in the identification, evaluation, and acquisition of royalties on various biopharmaceutical therapies. In addition, the company collaborates with innovators from academic institutions, research hospitals and not-for-profits, small and mid-cap biotechnology companies, and pharmaceutical companies.